Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma

Robert E. Bristow, Rae Lynn Baldwin, S. Diane Yamada, Murray Korc, Beth Y. Karlan

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND. Resistance to the potent growth inhibitory effects of transforming growth factor-β (TGF-β) is a characteristic of many malignancies. TGF-β insensitivity has been attributed to alterations in the number and function of the TGF-β receptors as well as disturbances of downstream signal transduction. Paradoxically, increased levels of TGF-β ligand have been demonstrated in several types of malignant tumors. TGF-β also may play a role in ovarian carcinogenesis; however, the nature of this interaction has yet to be defined completely. METHODS. To explore the potential role of TGF-β-mediated autocrine and paracrine influences in epithelial ovarian carcinoma, mRNA expression levels of the three TGF-β ligand isoforms (TGF-β1, TGF-β2, and TGF-β3) and the three TGF-β receptors (TβR-I, TβR-II, and TβR-III) were examined by Northern blot analysis in both primary and recurrent ovarian carcinoma specimens. Immunohistochemical analysis was performed to localize expression of TβR-I and TβR-II, whereas the presence of genetic alterations in TβR-I was examined through Southern blot analysis. RESULTS. Compared with normal ovarian tissue, both primary and recurrent ovarian carcinomas demonstrated significant overexpression of the TGF-β1 and TGF-β3 mRNA transcripts. TGF- β2 expression was detectable in 75% of primary and only 53% of recurrent tumor specimens. Alterations also were detected in TβR mRNA expression. Expression levels of TβR-III were significantly reduced in both primary and recurrent ovarian carcinomas. Furthermore, detectable levels of TβR-I and TβR-III mRNA transcripts were present in only 47% and 50% of recurrent ovarian tumors, respectively. Immunohistochemical staining demonstrated that TβR-I and TβR-II expression localized to tumor cells; however, receptor staining in stromal tissue also was detected. Southern blot analysis of TβR- I did not reveal any major genetic changes to account for the absence of TβR-I expression. CONCLUSIONS. Alterations in expression of TGF-β ligands and receptors consistently were greater in recurrent ovarian carcinomas compared with primary tumors, and may reflect a phenotype that promotes tumor recurrence or chemoresistance. Together, these data suggest that enhanced expression of TGF-β1 and TGF-β3, as well as the loss of expression of TβR- I and TβR-III, contribute to ovarian carcinogenesis and/or tumor progression.

Original languageEnglish (US)
Pages (from-to)658-668
Number of pages11
JournalCancer
Volume85
Issue number3
DOIs
StatePublished - Feb 1 1999
Externally publishedYes

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Ligands
Carcinoma
Neoplasms
Messenger RNA
Southern Blotting
Carcinogenesis
Staining and Labeling

Keywords

  • Iigand
  • Ovarian carcinoma
  • Receptor
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma. / Bristow, Robert E.; Baldwin, Rae Lynn; Yamada, S. Diane; Korc, Murray; Karlan, Beth Y.

In: Cancer, Vol. 85, No. 3, 01.02.1999, p. 658-668.

Research output: Contribution to journalArticle

Bristow, Robert E. ; Baldwin, Rae Lynn ; Yamada, S. Diane ; Korc, Murray ; Karlan, Beth Y. / Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma. In: Cancer. 1999 ; Vol. 85, No. 3. pp. 658-668.
@article{57bc57cd0c5c446c85c4683840680652,
title = "Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma",
abstract = "BACKGROUND. Resistance to the potent growth inhibitory effects of transforming growth factor-β (TGF-β) is a characteristic of many malignancies. TGF-β insensitivity has been attributed to alterations in the number and function of the TGF-β receptors as well as disturbances of downstream signal transduction. Paradoxically, increased levels of TGF-β ligand have been demonstrated in several types of malignant tumors. TGF-β also may play a role in ovarian carcinogenesis; however, the nature of this interaction has yet to be defined completely. METHODS. To explore the potential role of TGF-β-mediated autocrine and paracrine influences in epithelial ovarian carcinoma, mRNA expression levels of the three TGF-β ligand isoforms (TGF-β1, TGF-β2, and TGF-β3) and the three TGF-β receptors (TβR-I, TβR-II, and TβR-III) were examined by Northern blot analysis in both primary and recurrent ovarian carcinoma specimens. Immunohistochemical analysis was performed to localize expression of TβR-I and TβR-II, whereas the presence of genetic alterations in TβR-I was examined through Southern blot analysis. RESULTS. Compared with normal ovarian tissue, both primary and recurrent ovarian carcinomas demonstrated significant overexpression of the TGF-β1 and TGF-β3 mRNA transcripts. TGF- β2 expression was detectable in 75{\%} of primary and only 53{\%} of recurrent tumor specimens. Alterations also were detected in TβR mRNA expression. Expression levels of TβR-III were significantly reduced in both primary and recurrent ovarian carcinomas. Furthermore, detectable levels of TβR-I and TβR-III mRNA transcripts were present in only 47{\%} and 50{\%} of recurrent ovarian tumors, respectively. Immunohistochemical staining demonstrated that TβR-I and TβR-II expression localized to tumor cells; however, receptor staining in stromal tissue also was detected. Southern blot analysis of TβR- I did not reveal any major genetic changes to account for the absence of TβR-I expression. CONCLUSIONS. Alterations in expression of TGF-β ligands and receptors consistently were greater in recurrent ovarian carcinomas compared with primary tumors, and may reflect a phenotype that promotes tumor recurrence or chemoresistance. Together, these data suggest that enhanced expression of TGF-β1 and TGF-β3, as well as the loss of expression of TβR- I and TβR-III, contribute to ovarian carcinogenesis and/or tumor progression.",
keywords = "Iigand, Ovarian carcinoma, Receptor, Transforming growth factor-β",
author = "Bristow, {Robert E.} and Baldwin, {Rae Lynn} and Yamada, {S. Diane} and Murray Korc and Karlan, {Beth Y.}",
year = "1999",
month = "2",
day = "1",
doi = "10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M",
language = "English (US)",
volume = "85",
pages = "658--668",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Altered expression of transforming growth factor-β ligands and receptors in primary and recurrent ovarian carcinoma

AU - Bristow, Robert E.

AU - Baldwin, Rae Lynn

AU - Yamada, S. Diane

AU - Korc, Murray

AU - Karlan, Beth Y.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - BACKGROUND. Resistance to the potent growth inhibitory effects of transforming growth factor-β (TGF-β) is a characteristic of many malignancies. TGF-β insensitivity has been attributed to alterations in the number and function of the TGF-β receptors as well as disturbances of downstream signal transduction. Paradoxically, increased levels of TGF-β ligand have been demonstrated in several types of malignant tumors. TGF-β also may play a role in ovarian carcinogenesis; however, the nature of this interaction has yet to be defined completely. METHODS. To explore the potential role of TGF-β-mediated autocrine and paracrine influences in epithelial ovarian carcinoma, mRNA expression levels of the three TGF-β ligand isoforms (TGF-β1, TGF-β2, and TGF-β3) and the three TGF-β receptors (TβR-I, TβR-II, and TβR-III) were examined by Northern blot analysis in both primary and recurrent ovarian carcinoma specimens. Immunohistochemical analysis was performed to localize expression of TβR-I and TβR-II, whereas the presence of genetic alterations in TβR-I was examined through Southern blot analysis. RESULTS. Compared with normal ovarian tissue, both primary and recurrent ovarian carcinomas demonstrated significant overexpression of the TGF-β1 and TGF-β3 mRNA transcripts. TGF- β2 expression was detectable in 75% of primary and only 53% of recurrent tumor specimens. Alterations also were detected in TβR mRNA expression. Expression levels of TβR-III were significantly reduced in both primary and recurrent ovarian carcinomas. Furthermore, detectable levels of TβR-I and TβR-III mRNA transcripts were present in only 47% and 50% of recurrent ovarian tumors, respectively. Immunohistochemical staining demonstrated that TβR-I and TβR-II expression localized to tumor cells; however, receptor staining in stromal tissue also was detected. Southern blot analysis of TβR- I did not reveal any major genetic changes to account for the absence of TβR-I expression. CONCLUSIONS. Alterations in expression of TGF-β ligands and receptors consistently were greater in recurrent ovarian carcinomas compared with primary tumors, and may reflect a phenotype that promotes tumor recurrence or chemoresistance. Together, these data suggest that enhanced expression of TGF-β1 and TGF-β3, as well as the loss of expression of TβR- I and TβR-III, contribute to ovarian carcinogenesis and/or tumor progression.

AB - BACKGROUND. Resistance to the potent growth inhibitory effects of transforming growth factor-β (TGF-β) is a characteristic of many malignancies. TGF-β insensitivity has been attributed to alterations in the number and function of the TGF-β receptors as well as disturbances of downstream signal transduction. Paradoxically, increased levels of TGF-β ligand have been demonstrated in several types of malignant tumors. TGF-β also may play a role in ovarian carcinogenesis; however, the nature of this interaction has yet to be defined completely. METHODS. To explore the potential role of TGF-β-mediated autocrine and paracrine influences in epithelial ovarian carcinoma, mRNA expression levels of the three TGF-β ligand isoforms (TGF-β1, TGF-β2, and TGF-β3) and the three TGF-β receptors (TβR-I, TβR-II, and TβR-III) were examined by Northern blot analysis in both primary and recurrent ovarian carcinoma specimens. Immunohistochemical analysis was performed to localize expression of TβR-I and TβR-II, whereas the presence of genetic alterations in TβR-I was examined through Southern blot analysis. RESULTS. Compared with normal ovarian tissue, both primary and recurrent ovarian carcinomas demonstrated significant overexpression of the TGF-β1 and TGF-β3 mRNA transcripts. TGF- β2 expression was detectable in 75% of primary and only 53% of recurrent tumor specimens. Alterations also were detected in TβR mRNA expression. Expression levels of TβR-III were significantly reduced in both primary and recurrent ovarian carcinomas. Furthermore, detectable levels of TβR-I and TβR-III mRNA transcripts were present in only 47% and 50% of recurrent ovarian tumors, respectively. Immunohistochemical staining demonstrated that TβR-I and TβR-II expression localized to tumor cells; however, receptor staining in stromal tissue also was detected. Southern blot analysis of TβR- I did not reveal any major genetic changes to account for the absence of TβR-I expression. CONCLUSIONS. Alterations in expression of TGF-β ligands and receptors consistently were greater in recurrent ovarian carcinomas compared with primary tumors, and may reflect a phenotype that promotes tumor recurrence or chemoresistance. Together, these data suggest that enhanced expression of TGF-β1 and TGF-β3, as well as the loss of expression of TβR- I and TβR-III, contribute to ovarian carcinogenesis and/or tumor progression.

KW - Iigand

KW - Ovarian carcinoma

KW - Receptor

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=0033082311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033082311&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M

M3 - Article

C2 - 10091739

AN - SCOPUS:0033082311

VL - 85

SP - 658

EP - 668

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -